Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04040361

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

Non-small Cell Lung Cancer Stage II Clinical Trial

Official title:
Efficacy and Safety of Neoadjuvant Therapy of Pembrolizumab Combined With Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer: An Open-label Single-arm Phase II Study

Clinical Trial Summary

The efficacy and safety of the neoadjuvant therapy of pembrolizumab+ ramucirumab

Clinical Trial Description

To demonstrate the antitumor activity and safety of neoadjuvant pembrolizumab plus ramucirumab followed by surgery in patients with PD-L1 positive stage IB-IIIA non-small cell lung cancer ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04040361
Study type Interventional
Source National Cancer Center Hospital East
Contact Masahiro Tsuboi, Dr
Phone +81-4-7133-1111
Email energy@east.ncc.go.jp
Status Recruiting
Phase Phase 2
Start date November 30, 2019
Completion date November 30, 2025
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05451173 - Combining ICI With SBRT or HypoFrx-RT for ES NSCLC Phase 1/Phase 2
Recruiting NCT04586465 - Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC Phase 2
Completed NCT04342377 - The Canada Lymph Node Score Project: A Crossover Trial Phase 3
Completed NCT03550482 - Oncoxin® and Quality of Life in Cancer Patients Phase 4
Recruiting NCT06341387 - Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer
Completed NCT01991418 - Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC) N/A
Recruiting NCT04716946 - Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy Phase 2
Recruiting NCT06268613 - A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy Phase 1
Recruiting NCT05031533 - Dose-painting Radiation for LA-NSCLC N/A
Active, not recruiting NCT03383302 - SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects Phase 1/Phase 2
Recruiting NCT02622581 - Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Active, not recruiting NCT01795521 - LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC Phase 2
Recruiting NCT04585477 - Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) Phase 2
Not yet recruiting NCT05807893 - Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases Phase 2/Phase 3